Abstract. Mucinous colorectal carcinoma exhibits distinct clinicopathological features compared to non-mucinous colorectal carcinoma. Previous studies have discovered several molecular genetic features in mucinous colorectal carcinomas, but have limitations as they are confined to a small number of molecules. To understand the mucinous colorectal carcinoma system, this study was designed to identify genes that are differentially expressed in mucinous colorectal carcinoma compared to non-mucinous colorectal carcinoma using cDNA microarrays. cDNA microarray experiments were performed using human cDNA 17k chips with 25 mucinous and 27 non-mucinous cancer tissues. Differentially expressed genes (DEGs) were determined by Welch's t-test and more accurate classifiers were selected from the DEGs using the prediction analysis for microarrays (PAM) software package. Array results were validated using quantitative real-time RT-PCR. The identified gene set was functionally investigated through in silico analysis. Sixty-two DEGs were identified and the 50 highest ranking genes could be used to accurately classify mucinous and non-mucinous colorectal carcinomas. The identified gene set included up-regulated TFF1 (4-fold), AGR2 (3.3-fold), FSCN1 (2.2-fold), CD44 (1.5-fold) and down-regulated SLC26A3 (0.2-fold) in MC. TFF1, AGR2 and SLC26A3 were validated by quantitative real-time RT-PCR. The functions of these DEGs were related to tumorigenesis (14 genes), cell cycle progression (6 genes), invasion (2 genes), anti-apoptosis (7 genes), cell adhesion and proliferation (5 genes) and carbohydrate metabolism (3 genes). We suggest that MC has distinct molecular characteristics from NMC and therefore, that the expression signatures of DEGs may improve the understanding of molecular pathogenesis and clinical behaviors in MC.
Introduction
Mucinous colorectal carcinoma (MC) is a subtype of colorectal adenocarcinoma that is characterized by an extracellular mucin content of more than 50% of the tumor volume. MC has distinctive clinical and molecular features compared to non-mucinous colorectal carcinoma (NMC). Clinically, mucinous colorectal carcinoma tends to occur more frequently in patients who are less than 50 years old (1, 2) , be located in the right colon (1, 2) , present at an advanced stage, invade the adjacent viscera, have more extensive lymph node involvement (3) , and have a worse overall 5-year survival rate than NMC (4, 5) . Several studies have shown that genetic alterations and factors related to microsatellite instability (MSI) (6) (7) (8) (9) , CpG island methylator phenotype (CIMP) (9) , BRAF mutation (8-10), MUC2 and MUC5AC (11, 12) are related to MC.
Microarray technology has been adapted to profile thousands of genes simultaneously, and has demonstrated the potential use of expression profiles for the genome-wide molecular classification of cancer (13, 14) . We used a cDNA microarray technique to identify molecular features that discriminate MC and NMC. MC has distinct molecular features compared with NMC, and we suggest that these features may underlie the different cancer characteristics of colorectal cancer subtypes.
Materials and methods
Colorectal adenocarcinoma tissues. Fresh frozen tissues were obtained from colorectal cancer (CRC) patients who underwent curative surgical resection at the Yonsei Cancer Center, Severance Hospital in Seoul, Korea from 2003 to 2006. Pathologists at Severance Hospital strictly evaluated the histologies and mucin volumes of all tumors. Tumors were considered to be MC when mucin covered ≥50% of the microscopically observed areas. Tumors with mucin in 10% of the observed fields were classified as NMC. The tumors with 11-49% mucin content were classified as intermediate mucinous carcinoma (IMC) . Clinical information was collected from institutional medical records for all patients. The study protocol was approved by the Severance Hospital Institutional Review Board, and informed consent was obtained from patients for use of surgical specimens and clinicopathologic data for research purposes.
RNA preparation, amplification and cDNA microarray experiments. Total RNA was extracted from tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and amplified using the T7 linear amplification method according to the manufacturer's instructions. Yonsei reference RNA [Cancer Metastasis Research Center (CMRC), Seoul, Korea] was prepared by pooling equivalent amounts of the total RNA from 11 human cancer cell lines of various tumor types (15) . The cDNA microarray analysis was performed using a human cDNA 17k chip (CMRC-GT, Seoul, Korea) containing 17104 known genes and ESTs in a reference design following institutional protocols (15) .
Genomic DNA extraction and mutation analysis. Genomic DNA was extracted from tissue samples. The sequences of the BRAF and KRAS mutations were analyzed using a PyroMarkTMID sequencing machine and PyroMarkTMID 1.0 software (Biotage AB and Biosystems, Uppsala, Sweden). The analysis protocol and options were performed as per the manufacturer's recommendations. The BRAF gene mutation at position 600 (BRAFV600E) was assessed as described by a previous report (16) . Mutations in codon 12 and 13 of the KRAS gene were also determined by the Pyrosequencing technology with a slight modification of the previously reported method (8) .
Processes of sample selection and analysis. The processes of sample selection and analysis are summarized in Fig. 1 . Samples were divided into three sets, training, test and validation, for the selection of classifiers to discriminate MCs and NMCs. Twenty-five MCs were randomly selected from the CRC samples. Twenty-seven matched NMC samples having similar clinicopathologic factors with MCs were then selected and these 52 samples were used as a training set. Welch's t-test was performed to find DEGs discriminating MCs from NMCs in the training set. To identify better predictive genes, we used Prediction Analysis for Microarray (PAM) software (http://www-stat.stanford.edu/~tibs/PAM/) to conduct another test set consisting of 5 MCs and 4 NMCs. Finally, gene annotation of selected probes as classifiers was performed using the SOURCE database (http://source. stanford.edu). The predictive power of the selected gene set was validated using an independent validation set consisting of 27 NMCs and 2 MCs. Additionally, the robust prediction of classifiers for larger data sets, which consisted of the training, test, and validation sets, was confirmed using leaveone-out cross validation (LOOCV). For additional validation, IMC and signet-ring cell colorectal carcinoma samples were investigated by PAM analysis to determine the possibility of classification according to mucin volume. The validation of microarray results was conducted using real-time RT-PCR. utilized for the analysis of categorical data. PAM software v1.30.0 for R (pamr) and all processes for the predictions using PAM were conducted using scripts of pamr on R Cocoa GUI 1.16 (http://www.r-project.org/index.html). Prediction analyses using the Support Vector Machine (SVM) were performed with GeneSpring GX 7.3.1. Options for the SVM were as follows: i) gene selection method: all genes from selected list, ii) kernel function: polynorminal dot product (order 1 and 3) diagonal scaling factor, 10. LOOCV was executed using the GeneSpring GX 7.3.1 internal script and all options were set as those of SVM. The principal component analysis (PCA) was conducted using GeneSpring GX 7.3.1. The PCA on conditions was conducted and the mean centering and scaling method was used. Hierarchical clustering was performed using GeneSpring with complete linkage and Pearson correlation distance.
Quantitative real-time RT-PCR. TFF1, AGR2, SLC26A3 and MUC2 were selected for validation of the microarray data.
Quantitative real-time RT-PCR (qRT-PCR) was performed on 26 randomly selected samples from the 52 sample training set. Each reaction was run in duplicate using a Stratagene MX3005P Real-Time PCR System (Stratagene, La Jolla, CA, ONCOLOGY REPORTS 25: 717-727, 2011 Table I. Sample information. - Table II . Prediction results of the test and validation sets. 
a Sixty-two genes were initially selected through Welch's t-test.
b PAM, prediction analysis for microarray.
c SVM, support vector machine. Fifty genes were then determined from 62 genes via PAM analysis. USA). In brief, 4 μg of amplified RNA from each sample was reverse-transcribed using SuperScript II reverse transcriptase and random primers (Invitrogen). An aliquot of single stranded cDNA from each reverse-transcribed sample (1.4 μl) was PCR amplified using QuantiTect SYBR Green PCR (Qiagen, Valencia, CA, USA). Expression values for each gene were determined using a standard curve constructed from human genomic DNA (Promega, Madison, WI, USA). The housekeeping gene ACTB was selected for normalization and to construct a standard curve. Non-template-control wells without cDNA were included as negative controls. The primer sets for PCR amplification were designed as follows: TFF1-F:
5'-TACACCCACATCGAGAGCTG-3'. Student's t-test was used to assess the statistical differences in gene expression levels measured by qRT-PCR between the NMC and MC groups.
Prediction of biological functions. Investigation of biological roles was accomplished through the use of ingenuity pathways analysis (IPA, Ingenuity ® Systems, www.ingenuity.com). To construct a molecular network related to the determined functions, 11622 probes in the chip were used. The fold ratio (MCs/NMCs) for each probe was calculated, and then these values were parsed from the GeneSpring GX 7.3 to the IPA via the GeneSpring GX-IPA connector scripts.
Results
The selection of the training set and baseline characteristics.
To eliminate the effects of factors other than gene expression, ONCOLOGY REPORTS 25: 717-727, 2011 Table III. Continued.. 
Sixty-two genes were selected by Welch's t-test under a P-value threshold of 0.05. The final 50 genes selected with PAM analysis were exactly matched with the top 50 genes.
a The order of the 62 genes was concluded from the class prediction analysis using PAM, which was calculated based on the standardized centroids of genes for each class.
b The fold change was calculated as a base 2 logarithm of (average of normalized R/G ratio in MC samples)/(average of normalized R/G ratio in NMC samples).
c The false discovery rate (FDR) was calculated from Welch's t-test between MC and NMC samples with the Benjamini and Hochberg multiple testing correction.
-----------------------------------------------------------------------------------------------------
we selected 27 NMC samples with similar clinicopathologic factors to those of 25 MC samples including age, gender, tumor site, primary location, tumor depth and TNM stage (Table I) . Between the two groups, these factors were balanced and validated by the ¯2 test.
BRAF and KRAS mutations were examined in 49 (24 MCs with 25 NMCs) and 42 samples (23 MCs with 19 NMCs), respectively. Two of 49 (4%) had a BRAF mutation, and both were MC. Twelve of 42 (29%) had a KRAS mutation, and 5 were MC (5 of 23, 22%) and 7 were NMC (7 of 19, 37%). Although not statistically significant, there were more BRAF mutations and fewer KRAS mutations in MC samples compared to NMC samples.
The classification analysis of mucinous and non-mucinous carcinomas.
To find DEGs that can be used to discriminate between MC and NMC samples, we performed a Welch's t-test with the training set and 69 probes were selected with a threshold of false discovery rate of 0.05. After the annotation of 69 probes, 62 genes were determined to be DEGs and a classifier set (Table II) . We validated these 62 genes using two statistical methods, the prediction analysis for microarrays (PAM) and support vector machines (SVMs), which are used for classification of samples with expression data (Table III) . When using the gene signature, the prediction accuracy was 79.3 and 75.9% for PAM and SVM, respectively. Moreover, when the top 50 of 62 genes were used, the classification rate was 86.2 and 79.3% for PAM and SAM analysis, respectively, suggesting that the 50-gene signature provided better prediction accuracy.
In the two-way hierarchical clustering and principal component analysis (PCA), the selected 50-gene signature clearly discriminated samples into NMCs and MCs (Fig. 2) . However, in the case of intermediate mucinous carcinomas (IMC) and signet-ring cell carcinomas, samples could not be clearly classified based on the mucin contents.
Validation of selected classifiers. To investigate whether the 50-gene set could provide robust prediction for a larger data set, we performed LOOCV for all samples including the training, test, and validation sets. In this analysis, 81 out of 90 samples were correctly predicted (90%), showing better results in a large sample set than in an individual sample group. Finally, a 62-gene set that showed significant differential expression was selected and then the 50-gene set was shown to successfully discriminate MC and NMC.
The prediction of biological roles of selected DEGs. To functionally characterize the identified 62-gene set, the biological roles were investigated using Core Analysis in IPA 5.5 and various biological functions were predicted as major candidate functions with significant p-values. The top functions in the selected candidates were related to important cancer biological functions, including tumorigenesis (14 genes), cell cycle progression (6 genes), invasion (2 genes), anti-apoptosis (7 genes), and cell adhesion and proliferation (5 genes) together with carbohydrate metabolism (Table IV ). In addition, many genes belonging to these functions were high-ranked molecules in Table III and almost all genes were novel molecules that were not known to have a relationship to MC. However, expression alterations in these genes in MCs had a positive relationship with tumorigenesis, cell cycle, invasion, anti-apoptosis and proliferation, suggesting the possibility that MCs have more severe clinical characteristics.
Quantitative real-time RT-PCR for the validation of microarray results.
To validate the microarray results, we selected two highly up-regulated genes, TFF1 and AGR2, and one significantly down-regulated gene, SLC26A3, and performed qRT-PCR to compare expression between NMCs and MCs. In addition, we also analyzed MUC2, which is known to be up-regulated in MCs and to be expressed at a 3.02-fold higher level between MCs and NMCs based on microarray results. The first 3 genes were shown to be significantly up-or downregulated in MCs when compared to NMCs (Fig. 3A, P<0 .05). MUC2 was significantly up-regulated by 6.33-fold in MCs compared to NMCs (P<0.005). For all 4 genes, changes in expression observed by qRT-PCR showed concordant results with the array data (Fig. 3B) .
Discussion
Until now, most research on MC has focused on differences in clinical factors, variation of individual gene expression, and microsatellite instability. Frequent BRAF and infrequent KRAS mutations have been found in MC compared to NMC (8) (9) (10) . Though more BRAF and fewer KRAS mutations were also observed in our study, the incidence of mutations was not statistically significant. With regard to microsatellite instability (MSI) status, MC (36%) showed a higher incidence Table IV . Predicted biological functions and related genes of DEGs. (8, 9) . In addition, MC (41%) showed higher frequency of CpG island methylation phenotype than NMC (11%) (9) . The CpG island methylation phenotype is associated with transcriptional inactivation of the mismatch repair gene hMLH1. These genetic alterations are thought to Table IV . Continued. 
All fold changes are the base 2 logarithms of fold ratios (MCs/NMCs).
b FDR, false discovery rate.
- be related to the molecular pathways underlying the development of MC. Though MC is thought to be associated with worse prognoses (4, 5) , biological studies have been limited to several molecules (6) (7) (8) (9) (10) (11) (12) and investigating the role of multiple genes is required to understand the nature of MC. Therefore, we preformed gene expression profiling of MC, making this the first study to use high-density cDNA microarray as an approach to understanding the biology of MC.
To select the best classifiers, several factors should be considered including sampling for data analysis, accurate pathologic data, microarray chip quality and analysis method. Among these factors, sampling method was important in the initial data analysis process. We classified samples as three sets, the training set to determine classifiers discriminating MC and NMC, the test set to select more predictive classifiers from the training set result, and the validation set to evaluate the prediction accuracy of selected classifiers. As MC is generally about 5% of total CRC patients, there were not enough MC samples for three whole sets. Of the three sets, the sample size and balanced tumor types were more important in the training set, where the gene set was determined. For the test and validation sets, sufficient sample numbers were more important than the balance of sample types because this process aimed to evaluate the classifiers for predicting each samples correctly. Therefore, we composed three sets of MC and NMC samples as shown in Fig. 1 . Finally, we identified 50 genes that could classify the two groups with the best accuracy. In prediction and hierarchical clustering results, MC and NMC samples were clearly classified. However, intermediate mucinous carcinoma (IMC) and signet-ring cell carcinoma were not clearly classified based on their mucin component. These results might have arisen from a narrow distribution of mucin components and heterogeneous molecular characteristics.
To understand the molecular mechanisms underlying differences in clinical characteristics, we assessed molecular signatures of MC and NMC using significant DEGs. As a result, several biological functions implicated in cancer development and progression were selected (Table IV) . These functions were tumorigenesis, cell cycle and cell proliferation, and almost all genes were novel molecules that had not previously been reported to be involved in MC. Among these genes, several genes were known to have a role associated with colorectal carcinoma. SLC26A3 is known to be transcriptionally down-regulated in the early neoplastic process and underexpressed or absent in colon cancer samples compared with their normal counterparts (17) (18) (19) . SLC26A3 dramatically suppressed colony formation and cell growth of various cancer cell lines, including colorectal cancer cells (20) . In our results, SLC26A3 was significantly down-regulated in MCs and down-regulation was also clearly confirmed in the quantitative real-time RT-PCR analysis (Fig. 3) , which suggests that SLC26A3 is involved in the carcinogenesis of MCs. FSCN1 increased invasiveness and proliferation of colon epithelial cell lines (21) . Up-regulation of FSCN1 was also associated with ER-negative breast carcinoma and a more aggressive clinical outcome (22) . In our results, FSCN1 was more up-regulated in MCs than in NMCs, which supports the worse prognosis with MC. CD44 and TFF1 are key molecules with multiple functions. CD44 is a well-known transmembrane glycoprotein that plays a critical role in a variety of cellular behavior, including adhesion, migration, invasion and survival. In a previous report, it was reported that activation of CD44 decreases apoptosis of colon cancer cell lines (23) and increases adhesion of colorectal carcinoma cell lines and endothelial cell lines (24) . In our results, expression of CD44 had an effect on tumor survival and proliferation. TFF1 is a secretory protein expressed in gastrointestinal mucosa. While the function of this gene is not well understood, it is thought to protect the mucosa from insults, stabilize the mucus layer, and affect healing of the epithelium. It has been reported that TFF1 could have important roles in apoptosis, tumorigenesis, invasion, and migration of colorectal cancer. TFF1 decreased apoptosis of colon cells (25) , and increased invasiveness (26, 27) . Especially, TFF1 was expressed more intensively in stage A and B compared to C and D colorectal cancer tissues and was highly expressed in metastasized liver tissue (26) . Immunohistochemistry studies revealed MC-specific staining of TFF1 (12) . In our results, TFF1 was up-regulated in MCs compared to NMCs and in stage II compared to III and IV by 1.5-fold (data not shown). Further, in quantitative realtime RT-PCR, TFF1 was significantly up-regulated in MCs compared to NMCs (Fig. 3) . In conclusion, TFF1 may play important roles in tumorigenesis, anti-apoptosis and invasiveness of MCs.
In our study, through the use of Core Analysis in IPA, three top ranked networks with selected DEGs were determined together with the biological roles, including cellular movement, cell-to-cell signaling and interaction and cell cycle (data not shown). This analysis provided valuable evidence to support the distinct molecular characteristics of MC, which will ultimately improve our understanding of the carcinogenesis of MC.
Using microarray analysis, we identified 50 classifiers out of 62 differentially expressed genes in mucinous carcinoma compared to non-MC. These genes were associated with tumorigenesis, invasion, cell cycle progression, anti-apoptosis, cell adhesion and proliferation. Based on the results of this study, we suggest that MCs have distinct molecular characteristics from NMC, and that the selected gene set provides a basis for a better understanding of the molecular pathogenesis of mucinous colorectal adenocarcinoma.
